J Uehlinger|L M Aledort - JoVE Visualize

Showing results (81-90 of 108) with videos related to

Pageof 11

Sort By:

Blood|August 1, 1985

A study of liver biopsies and liver disease among hemophiliacsL M Aledort, P H Levine, M Hilgartner, et al.

BMJ (Clinical Research Ed.)|January 25, 1992

Variability in serial CD4 counts and relation to progression of HIV-I infection to AIDS in haemophilic patients. Transfusion Safety Study GroupL M Aledort, M W Hilgartner, M C Pike, et al.

Blood|November 1, 1983

Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIIIJ M Lusher, P M Blatt, J A Penner, et al.

Intensive Care Medicine|May 1, 1996

Neonatal lupus erythematosus with congenital heart block and severe heart failure due to myocarditis and endocardititis of the mitral valveG Ferrazzini, M Fasnacht, U Arbenz, et al.

Developmental Biology|February 1, 1990

Analysis of the hotfoot (ho) locus by creation of an insertional mutation in a transgenic mouseJ W Gordon, J Uehlinger, N Dayani, et al.

Lancet (London, England)|September 18, 1993

Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune statusS V Seremetis, L M Aledort, G E Bergman, et al.

Archives of Internal Medicine|June 1, 1989

The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experienceD B Brettler, A D Forsberg, P H Levine, et al.

Lancet (London, England)|September 17, 1994

Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Multicenter Hemophilia Cohort StudyJ J Goedert, A R Cohen, C M Kessler, et al.

Transfusion|February 1, 1992

Low risk of viral infection after administration of vapor-heated factor VIII concentrate. International Investigator GroupP M Mannucci, K Schimpf, T Abe, et al.

Blood|August 15, 1993

Effect on lymphocyte subsets of clotting factor therapy in human immunodeficiency virus-1-negative congenital clotting disorders. The Transfusion Safety Study GroupJ Hassett, G F Gjerset, J W Mosley, et al.

Pageof 11

Showing results (81-90 of 108) with videos related to

Sort By:

Pageof 11

Blood|August 1, 1985

A study of liver biopsies and liver disease among hemophiliacsL M Aledort, P H Levine, M Hilgartner, et al.

BMJ (Clinical Research Ed.)|January 25, 1992

Variability in serial CD4 counts and relation to progression of HIV-I infection to AIDS in haemophilic patients. Transfusion Safety Study GroupL M Aledort, M W Hilgartner, M C Pike, et al.

Blood|November 1, 1983

Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIIIJ M Lusher, P M Blatt, J A Penner, et al.

Intensive Care Medicine|May 1, 1996

Neonatal lupus erythematosus with congenital heart block and severe heart failure due to myocarditis and endocardititis of the mitral valveG Ferrazzini, M Fasnacht, U Arbenz, et al.

Developmental Biology|February 1, 1990

Analysis of the hotfoot (ho) locus by creation of an insertional mutation in a transgenic mouseJ W Gordon, J Uehlinger, N Dayani, et al.

Lancet (London, England)|September 18, 1993

Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune statusS V Seremetis, L M Aledort, G E Bergman, et al.

Archives of Internal Medicine|June 1, 1989

The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experienceD B Brettler, A D Forsberg, P H Levine, et al.

Lancet (London, England)|September 17, 1994

Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Multicenter Hemophilia Cohort StudyJ J Goedert, A R Cohen, C M Kessler, et al.

Transfusion|February 1, 1992

Low risk of viral infection after administration of vapor-heated factor VIII concentrate. International Investigator GroupP M Mannucci, K Schimpf, T Abe, et al.

Blood|August 15, 1993

Effect on lymphocyte subsets of clotting factor therapy in human immunodeficiency virus-1-negative congenital clotting disorders. The Transfusion Safety Study GroupJ Hassett, G F Gjerset, J W Mosley, et al.

Pageof 11